Navigation Links
LSUHSC awarded NIH grant to develop pneumonia vaccine
Date:10/7/2011

New Orleans, LA Dr. Judd Shellito, Chief of the Section of Pulmonary and Critical Care Medicine at LSU Health Sciences Center New Orleans, has been awarded approximately $9 million in grant funding to develop a vaccine against Pneumocystis, an important cause of pneumonia in people with HIV infection. This potentially fatal illness is the most common serious opportunistic infection in people with HIV. The 5-year grant was awarded by the National Heart Lung and Blood Institute of the National Institutes of Health.

According to the Centers for Disease Control and Prevention, Pneumocystis pneumonia (PCP), which is caused by Pneumocystis jirovecii (formerly P. carinii), is frequently the first serious illness encountered by HIV-infected persons. During the early years of the AIDS epidemic, PCP was the AIDS-defining illness for as many as two thirds of patients in the United States. Patients in the developing world without access to PCP prophylaxis or antiretroviral drugs remain at high risk, and PCP continues to develop in certain groups in industrialized countries. There is also a potential for drug resistance to develop.

While officially classified as a fungal pneumonia, Pneumocystis pneumonia does not respond to antifungal treatment. The fungus that causes it is common in the environment and does not cause illness in healthy people. Besides those with HIV, it can also cause lung infection in people whose immune function is suppressed due to cancer, chronic use of corticosteroids or other medications that weaken the immune system, or organ or bone marrow transplants.

Dr. Shellito, who is also the Lowenstein Professor and Vice Chair for Research in the Department of Medicine at LSU Health Sciences Center New Orleans' School of Medicine, has served as principal investigator on this Program Project grant which has been funded by the National Institutes of Health for 11 years. At the conclusion of the project, it will have brought nearly $17 million in federal funding to LSU Health Sciences Center New Orleans. Dr. Shellito is collaborating with Dr. Jay Kolls, who holds faculty appointments at both LSU Health Sciences Center New Orleans and the University of Pittsburgh.

"Lung infections remain an important problem for individuals infected with the HIV virus," notes Dr. Shellito. "Of these infections, one of the most severe is pneumonia caused by the fungal pathogen, Pneumocystis. This project seeks to develop a safe and effective vaccine not just to treat Pneumocystis pneumonia but to prevent it altogether. We believe that such a vaccine will lower the cost of treatment of HIV and improve the quality of life for individuals living with HIV."


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related medicine news :

1. Grant to LSUHSC Tumor Registry creates pediatric cancer research tool
2. Protein discovered at LSUHSC may suppress breast cancer growth
3. LSUHSC research finds protein that protects cancer cells from chemo and radiation therapy
4. LSUHSC research shows emotional stress can change brain function
5. APA gives LSUHSC psychiatry gold award for program in St. Bernard schools after Katrina
6. LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI
7. LSUHSC study finds early predictors of metabolic syndrome in healthy 7-9 year-olds
8. Cothenius Medal awarded to Arizona State University social insect scientist for lifes work
9. Penn veterinarian Ralph Brinster awarded National Medal of Science
10. Lung cancer research team awarded $1.43 million to study cancer in Eastern Kentucky
11. UT awarded NIH grants to study prevention and treatment of neurodegenerative and vascular diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Miami Periodontist ... 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held ... its annual Global Symposium at the Fontainebleau Hotel located in Miami Beach, FL. ...
(Date:4/24/2017)... Greensboro, NC and Seattle, WA (PRWEB) , ... ... ... currently utilized by 75+ leading lifestyle brands, work wear distributors and International relief ... diseases they can carry. The company also offers lifestyle and work wear collections ...
(Date:4/24/2017)... ... April 24, 2017 , ... A 2-in-1 ... the same place. From 101 Water Texas, here are the ways in which ... enjoy a continuous supply of pure, fresh, oxygenated water, with both cold and ...
(Date:4/23/2017)... , ... April 23, 2017 , ... ... managed services announced the achievement of Cisco Select certification and SMB specialization. ... United States. , In earning the Select Certification, Altura fulfilled the ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of the Year, ... providing information destruction , recycling, and compliance services to businesses throughout ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
Breaking Medicine Technology: